Impact News +++ ABIONYX Pharma Is Launching a Capital Increase With Cancellation of Preferential Subscription Rights in... (Business Wire) +++ ABIONYX Aktie -4,27%

CRISPR THERAPEUTICS Aktie

>Aktienkurs

48.2 EUR +0.8% (Tradegate)

Ask: 48.2 EUR / 2000 Stück

Bid: 47.2 EUR / 2000 Stück

Tagesumsatz: 1141 Stück

Realtime Kurs von 7:30 bis 22 Uhr!

Aktie über LYNX handeln

Intraday

1 Jahr

>Performance

1 Woche: -0,4%

1 Monat: +6,6%

3 Monate: -8,2%

6 Monate: +33,1%

1 Jahr: -28,0%

laufendes Jahr: -28,0%

>CRISPR THERAPEUTICS Aktie

Name:

CRISPR THERAPEUTICS

Land:

Schweiz

Sektor:

Gesundheit

ISIN/ Wkn:

CH0334081137 / A2AT0Z

Symbol/ Ticker:

1CG (Frankfurt) / CRSP (NASDAQ)

Kürzel:

FRA:1CG, ETR:1CG, 1CG:GR, NASDAQ:CRSP

Index:

Webseite:

https://crisprtx.com/

Profil:

Crispr Therapeutics AG is a biotechnology company ..
>Volltext..

Marktkapitalisierung:

4715.41 Mio. EUR

Unternehmenswert:

3260.2 Mio. EUR

Umsatz:

32.65 Mio. EUR

EBITDA:

-391.44 Mio. EUR

Nettogewinn:

-415.92 Mio. EUR

Gewinn je Aktie:

-4.75 EUR

Schulden:

179.74 Mio. EUR

Liquide Mittel:

247.02 Mio. EUR

Operativer Cashflow:

-257.65 Mio. EUR

Bargeldquote:

16.13

Umsatzwachstum:

-82.07%

Gewinnwachstum:

-93.38%

Dividende je Aktie:

Dividendenrendite:

Dividendenschätzung:

Insiderhandel:

Suchwörter:

CRISPR THERAPEUTICS

Letzte Datenerhebung:

16.12.25

>Kennzahlen

Aktien/ Unternehmen:

Aktien: 95.3 Mio. St.

Frei handelbar: 96.02%

Leerverk. Aktien: 23.54%

Rückkaufquote: -5.9%

Mitarbeiter: 393

Umsatz/Mitarb.: 0.08 Mio. EUR

Analysten:

Analystenrating: Buy

Kursziel: 33.25%

Bewertung:

KGV: -

KGV lG: -

KUV: 137.52

KBV: 2.9

PEG-Ratio: -0.11

EV/EBITDA: -

Rentabilität:

Bruttomarge: -365.23%

Gewinnmarge: -1273.7%

Operative Marge: -1247.21%

Managementeffizenz:

Gesamtkaprendite: -21.7%

Eigenkaprendite: -25.33%

>Peer Group

Es sind 39 Aktien bekannt.

>Chart & Kurs - NASDAQ

>Alle News

10.12.25 - 19:01	Why Is CRISPR Therapeutics (CRSP) Up 3.3% Since Last Earnings Report? (Zacks)
	CRISPR Therapeutics (CRSP) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues....

01.12.25 - 17:57	Crispr Therapeutics pares loss amid takeover speculation (SeekingAlpha)
	Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...

17.11.25 - 17:15	Crispr Therapeutics gains amid takeover speculation (SeekingAlpha)
	Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...

12.11.25 - 23:48	ARK Sold Almost 400,000 Shares of CRISPR Therapeutics. Is Cathie Wood Worried? (Fool)
	Um den gesamten Artikel unter fool.com zu lesen, klicken Sie bitte auf die Überschrift...

11.11.25 - 16:03

CRISPR Therapeutics′ Investigational Gene Therapy Shows Promising Lipid-Lowering Effects In Early Trial (Benzinga)

CRISPR Therapeutics' CTX310 trial shows strong, sustained lipid reductions and favorable safety, boosting confidence in its gene editing platform. Latest Ratings for CRSP DateFirmActionFromTo Feb 2022RBC CapitalMaintainsSector Perform Feb 2022SVB LeerinkMaintainsOutperform Dec 2021Cowen & Co.Initiates Coverage OnMarket Perform View More Analyst Ratings for CRSP View the Latest Analyst Ratings read more...

10.11.25 - 14:12	CRISPR Therapeutics GAAP EPS of -$1.17 beats by $0.07, revenue of $0.89M (SeekingAlpha)
	Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...

08.11.25 - 16:00	CRISPR Therapeutics Announces Positive Phase 1 Clinical Data for CTX310® Demonstrating Deep and Durable ANGPTL3 Editing, Triglyceride and Lipid Lowering (GlobeNewswire EN)
	-Data presented in a late-breaking presentation at the American Heart Association (AHA) Scientific Sessions 2025-...

08.11.25 - 01:01	CRISPR Therapeutics AG (CRSP) Stock Drops Despite Market Gains: Important Facts to Note (Zacks)
	The latest trading day saw CRISPR Therapeutics AG (CRSP) settling at $55.16, representing a -2.56% change from its previous close....

21.10.25 - 01:01	Insiderhandel: Chief Executive Officer verkauft Aktien von Crispr Therapeutics im Wert von 3456279 USD (Insiderkauf)
	Kulkarni, Samarth - Vorstand - Tag der Transaktion: 2025-10-17...

16.10.25 - 11:54	CRISPR Therapeutics files for $600M stock offering (SeekingAlpha)
	Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...

16.10.25 - 10:36	New to Growth Stocks? Here′s 1 Every Investor Should Have on Their Radar. (Fool)
	CRISPR Therapeutics is a promising mid-cap biotech stock with an approved product in its portfolio....

16.10.25 - 03:01	Insiderhandel: Chief Executive Officer verkauft Aktien von Crispr Therapeutics im Wert von 282517 USD (Insiderkauf)
	Kulkarni, Samarth - Vorstand - Tag der Transaktion: 2025-10-14...

16.10.25 - 03:01	Insiderhandel: General Counsel and Secretary verkauft Aktien von Crispr Therapeutics im Wert von 71662 USD (Insiderkauf)
	Kasinger, James R. - Vorstand - Tag der Transaktion: 2025-10-14...

14.10.25 - 01:45	CRISPR Therapeutics AG (CRSP) Stock Sinks As Market Gains: What You Should Know (Zacks)
	In the most recent trading session, CRISPR Therapeutics AG (CRSP) closed at $68.29, indicating a -6.54% shift from the previous trading day....

10.10.25 - 14:03	CRISPR Therapeutics Presents New Preclinical Data for CTX460™ Demonstrating In Vivo Gene Correction of Alpha-1 Antitrypsin Deficiency (AATD) Utilizing Novel SyNTase™ Editing Platform (GlobeNewswire EN)
	-Preclinical data presented at the European Society of Gene and Cell Therapy (ESGCT) highlight a potential best-in-class profile-...

10.10.25 - 01:45	CRISPR Therapeutics AG (CRSP) Sees a More Significant Dip Than Broader Market: Some Facts to Know (Zacks)
	CRISPR Therapeutics AG (CRSP) closed the most recent trading day at $74.89, moving 2.46% from the previous trading session....

09.10.25 - 13:00	CRISPR Therapeutics (CRSP) Surges 8.7%: Is This an Indication of Further Gains? (Zacks)
	CRISPR Therapeutics (CRSP) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term....

07.10.25 - 16:45	Here is What to Know Beyond Why CRISPR Therapeutics AG (CRSP) is a Trending Stock (Zacks)
	CRISPR Therapeutics (CRSP) has received quite a bit of attention from Zacks.com users lately. Therefore, it is wise to be aware of the facts that can impact the stock's prospects....

04.10.25 - 01:45	CRISPR Therapeutics AG (CRSP) Stock Falls Amid Market Uptick: What Investors Need to Know (Zacks)
	CRISPR Therapeutics AG (CRSP) reached $67.74 at the closing of the latest trading day, reflecting a -6.98% change compared to its last close....

01.10.25 - 14:03

CRISPR Therapeutics to Present Preclinical Data on Alpha-1 Antitrypsin Deficiency (AATD) Utilizing Novel SyNTase Gene Editing Technology at the European Society of Gene and Cell Therapy (ESGCT) 2025 Annual Congress (GlobeNewswire EN)

ZUG, Switzerland and BOSTON, Oct. 01, 2025 (GLOBE NEWSWIRE) -- CRISPR Therapeutics (Nasdaq: CRSP), a biopharmaceutical company focused on creating transformative gene-based medicines for serious diseases, today announced the acceptance of an abstract for oral presentation at the European Society of Gene and Cell Therapy (ESGCT) 2025 Annual Congress, taking place October 7-10, 2025. The presentation will introduce the Company's novel SyNTase gene editing technology and highlight its application in single-dose in vivo gene correction to treat Alpha-1 Antitrypsin Deficiency (AATD), a rare genetic disorder....

>weitere News anzeigen...

>Impressum >Über uns >Datenschutz >Financial Data & Solutions

>Behalte deine Investments mit realtime Kursen & News im Blick. Finde neue spannende Aktien! Registriere Dich und werde Mitglied!

Zitat des Tages: Der Mensch ward zum Tun und nicht zum Vernünfteln erschaffen. Aber eben deswegen, weil er nicht dazu erschaffen ward, hängt er diesem mehr als jenem nach. - Gotthold Ephraim Lessing

Partner: >Tradegate Börse | >Dukascopy | >Boersentreff- Partner

Börsentreff auf Facebook |

Börsentreff auf X |

Börsentreff auf Instagram